Clinical value of ultradeep HIV-1 genotyping and tropism testing in late presenters with advanced disease
This article aims to investigate if the detection of preexisting drug-resistant minority variant (DRMV) and/or X4 HIV-1 variants could improve the efficacy of first-line combined antiretroviral therapy (ART) in late presenters. Post-hoc, combined analysis of two open-label, prospective, randomized clinical trials comparing first-line ART with efavirenz (EFV) vs. ritonavir-boosted protease inhibitor (PI/r)-based regimens in ART-naive, HIV-1-infected patients, with CD4 T-cell counts less than 100 cells/μl and wild-type HIV-1 by bulk sequencing. Pre-ART samples were reanalyzed for the presence of DRMVs and X4 HIV-1 using 454 sequencing. Kaplan-Meier curves and Cox regression were used to evaluate the association between X4 HIV and DRMVs and risk of virological failure. From 141 evaluable patients, 57 received EFV, and 84 received PI/r, including first-line ART. Median pre-ART CD4 T-cell counts and HIV-1 RNA levels were 39 cells/μl and 257 424 copies/ml, respectively; 35.5% of patients had X4 HIV variants. Detection of DRMVs leading to an ART-specific cumulative HIVdb score of at least 10 increased the risk of virological failure in patients initiating EFV [log-rank P = 0.048, hazard ratio = 4.3 (95% confidence interval: 0.8, 25.0), P = 0.074], but not in those starting PI/r. Presence of X4 HIV did not affect virological outcomes, but was associated with impaired CD4 T-cell count recovery over 2 years (214 vs. 315 cells/μl with X4 vs. R5 HIV-1 tropism, respectively, P = 0.017). Accounting for preexisting DRMVs may improve the outcomes of first-line nonnucleoside reverse transcriptase inhibitor-based ART in late presenters with advanced immune suppression. Presence of X4 HIV-1 at diagnosis predicts impaired immune restoration under ART..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
|---|---|
| Enthalten in: |
Aids |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Casadellà, Maria [VerfasserIn] |
|---|
| Links: |
|---|
| BKL: |
|---|
| RVK: |
|---|
| doi: |
10.1097/QAD.0000000000000748 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC1957658509 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC1957658509 | ||
| 003 | DE-627 | ||
| 005 | 20230515070519.0 | ||
| 007 | tu | ||
| 008 | 160206s2015 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1097/QAD.0000000000000748 |2 doi | |
| 028 | 5 | 2 | |a PQ20160617 |
| 035 | |a (DE-627)OLC1957658509 | ||
| 035 | |a (DE-599)GBVOLC1957658509 | ||
| 035 | |a (PRQ)c1281-64d86d748a0f97bc28c4c083799eedabd270b24733c1eb9fd466f7d20e35b6a20 | ||
| 035 | |a (KEY)0157957620150000029001201493clinicalvalueofultradeephiv1genotypingandtropismte | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q DNB |
| 084 | |a XA 16838 |q AVZ |2 rvk | ||
| 084 | |a 44.78 |2 bkl | ||
| 100 | 1 | |a Casadellà, Maria |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical value of ultradeep HIV-1 genotyping and tropism testing in late presenters with advanced disease |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a This article aims to investigate if the detection of preexisting drug-resistant minority variant (DRMV) and/or X4 HIV-1 variants could improve the efficacy of first-line combined antiretroviral therapy (ART) in late presenters. Post-hoc, combined analysis of two open-label, prospective, randomized clinical trials comparing first-line ART with efavirenz (EFV) vs. ritonavir-boosted protease inhibitor (PI/r)-based regimens in ART-naive, HIV-1-infected patients, with CD4 T-cell counts less than 100 cells/μl and wild-type HIV-1 by bulk sequencing. Pre-ART samples were reanalyzed for the presence of DRMVs and X4 HIV-1 using 454 sequencing. Kaplan-Meier curves and Cox regression were used to evaluate the association between X4 HIV and DRMVs and risk of virological failure. From 141 evaluable patients, 57 received EFV, and 84 received PI/r, including first-line ART. Median pre-ART CD4 T-cell counts and HIV-1 RNA levels were 39 cells/μl and 257 424 copies/ml, respectively; 35.5% of patients had X4 HIV variants. Detection of DRMVs leading to an ART-specific cumulative HIVdb score of at least 10 increased the risk of virological failure in patients initiating EFV [log-rank P = 0.048, hazard ratio = 4.3 (95% confidence interval: 0.8, 25.0), P = 0.074], but not in those starting PI/r. Presence of X4 HIV did not affect virological outcomes, but was associated with impaired CD4 T-cell count recovery over 2 years (214 vs. 315 cells/μl with X4 vs. R5 HIV-1 tropism, respectively, P = 0.017). Accounting for preexisting DRMVs may improve the outcomes of first-line nonnucleoside reverse transcriptase inhibitor-based ART in late presenters with advanced immune suppression. Presence of X4 HIV-1 at diagnosis predicts impaired immune restoration under ART. | ||
| 700 | 1 | |a Manzardo, Christian |4 oth | |
| 700 | 1 | |a Noguera-Julian, Marc |4 oth | |
| 700 | 1 | |a Ferrer, Elena |4 oth | |
| 700 | 1 | |a Domingo, Pere |4 oth | |
| 700 | 1 | |a Pérez-Álvarez, Susana |4 oth | |
| 700 | 1 | |a Podzamczer, Daniel |4 oth | |
| 700 | 1 | |a Plana, Montserrat |4 oth | |
| 700 | 1 | |a Clotet, Bonaventura |4 oth | |
| 700 | 1 | |a Gatell, José M |4 oth | |
| 700 | 1 | |a Miró, José M |4 oth | |
| 700 | 1 | |a Paredes, Roger |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Aids <London> |d Hagerstown, Md. : Lippincott Williams & Wilkins, 1987 |g 29(2015), 12, Seite 1493 |w (DE-627)168132583 |w (DE-600)639076-6 |w (DE-576)015929418 |x 0269-9370 |7 nnns |
| 773 | 1 | 8 | |g volume:29 |g year:2015 |g number:12 |g pages:1493 |
| 856 | 4 | 1 | |u http://dx.doi.org/10.1097/QAD.0000000000000748 |3 Volltext |
| 856 | 4 | 2 | |u http://www.ncbi.nlm.nih.gov/pubmed/26244389 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a GBV_ILN_2414 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4219 | ||
| 936 | r | v | |a XA 16838 |
| 936 | b | k | |a 44.78 |q AVZ |
| 951 | |a AR | ||
| 952 | |d 29 |j 2015 |e 12 |h 1493 | ||